Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H (3378) Stock Statistics & Valuation Metrics
Total Valuation
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has a market cap or net worth of HKD 3.86B. The enterprise value is HKD 12139.07T.
- Market Cap
- HKD 3.86B
- Enterprise Value
- HKD 12139.07T
Share Statistics
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has 136,218,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 136,218,830
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 4.06%.
- Return on Equity (ROE)
- 0.13
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 4.06%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 428.17M
- Profits Per Employee
- 12.82M
- Employee Count
- 60
- Asset Turnover
- ―
- Inventory Turnover
- ―
Valuation Ratios
The current PE Ratio of Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H is 85.77. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s PEG ratio is 112.57.
- PE Ratio
- 85.77
- PS Ratio
- 0.13
- PB Ratio
- 11.12
- Price to FCF
- 1.68
- Price to Operating Cash Flow
- 34.07
- PEG Ratio
- 112.57
Income Statement
In the last 12 months, Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H had revenue of 25.69B and earned 769.11M in profits. Earnings per share was 0.28.
- Revenue
- 25.69B
- Gross Profit
- 1.38B
- Operating Income
- 1.20B
- Pretax Income
- 983.82M
- Net Income
- 769.11M
- EBITDA
- 1.29B
- Earnings Per Share (EPS)
- 0.28
Cash Flow
In the last 12 months, operating cash flow was 676.38M and capital expenditures -346.62M, giving a free cash flow of 329.75M billion.
- Operating Cash Flow
- 676.38M
- Free Cash Flow
- 329.75M
- Free Cash Flow per Share
- 0.70
Dividends & Yields
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 59.69%
- Earnings Yield
- 1.17%
Stock Price Statistics
- Beta
- 0.22
- 52-Week Price Change
- 64.88%
- 50-Day Moving Average
- 28.50
- 200-Day Moving Average
- 26.61
- Relative Strength Index (RSI)
- 54.52
- Average Volume (3m)
- 19.95K
Financial Position
- Current Ratio
- ―
- Quick Ratio
- ―
- Debt to Market Cap
- ―
- Net Debt to EBITDA
- 9.64
- Interest Coverage Ratio
- ―
Taxes
In the past 12 months, Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has paid 214.71M in taxes.
- Income Tax
- 214.71M
- Effective Tax Rate
- ―
Enterprise Valuation
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H EV to EBITDA ratio is 9.48, with an EV/FCF ratio of 6.36.
- EV to Sales
- 0.48
- EV to EBITDA
- 9.48
- EV to Free Cash Flow
- 6.36
- EV to Operating Cash Flow
- 6.36
Balance Sheet
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has HKD 2.46B in cash and marketable securities with HKD 7.54B in debt, giving a net cash position of -HKD 5.08B billion.
- Cash & Marketable Securities
- HKD 2.46B
- Total Debt
- HKD 7.54B
- Net Cash
- -HKD 5.08B
- Net Cash Per Share
- -HKD 37.30
- Tangible Book Value Per Share
- ―
Margins
Gross margin is 5.35%, with operating margin of 4.68%, and net profit margin of 2.99%.
- Gross Margin
- 5.35%
- Operating Margin
- 4.68%
- Pretax Margin
- 3.83%
- Net Profit Margin
- 2.99%
- EBITDA Margin
- 5.02%
- EBIT Margin
- 5.02%
Analyst Forecast
The average price target for Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -22.56%
Scores
- Smart Score
- 7
- AI Score
- ―